Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 1839100 in Healthy Men
NCT05354453Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 1839100 in pulmonary fibrosis (PF) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator at 10 days. Started May 2022; status: completed.
02
Drugs
BI 1839100
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT05354453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05354453.